Industry
Biotechnology
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Lisa Levin
October 16, 2023 | 5:09 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2023 | 11:02 am
Portfolio Pulse from Happy Mohamed
August 14, 2023 | 4:12 pm
Portfolio Pulse from richadhand@benzinga.com
August 09, 2023 | 1:50 pm
Portfolio Pulse from richadhand@benzinga.com
June 26, 2023 | 10:48 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.